NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.42 BRL | +19.48% |
|
+1.13% | +54.35% |
| 06-20 | WHO Issues First Medical Product Notice Amid Reports of Counterfeit Batches of Novo Nordisk's Ozempic | MT |
| 06-20 | WHO issues warnings on falsified diabetes and weight-loss drugs | RE |
| Sales 2024 * | 291B 41.8B 228B 3,303B | Sales 2025 * | 352B 50.49B 275B 3,990B | Capitalization | 4,408B 633B 3,444B 49,999B |
|---|---|---|---|---|---|
| Net income 2024 * | 105B 15.03B 81.79B 1,187B | Net income 2025 * | 128B 18.33B 99.79B 1,449B | EV / Sales 2024 * | 15.2 x |
| Net Debt 2024 * | 22.09B 3.17B 17.26B 251B | Net cash position 2025 * | 6.04B 866M 4.72B 68.46B | EV / Sales 2025 * | 12.5 x |
| P/E ratio 2024 * |
42.6
x | P/E ratio 2025 * |
34.8
x | Employees | 66,015 |
| Yield 2024 * |
1.19% | Yield 2025 * |
1.46% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +19.48% | ||
| 1 week | +1.13% | ||
| Current month | +7.13% | ||
| 1 month | +11.11% | ||
| 3 months | +18.74% | ||
| 6 months | +52.47% | ||
| Current year | +54.35% |
1 week
92.08
97.90
1 month
83.0097.90
Current year
61.7497.90
1 year
45.59102.61
3 years
30.55102.61
5 years
30.55102.61
10 years
30.55102.61
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/12/90 | |
| Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 18/03/15 |
Helge Lund
CHM | Chairman | 61 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 96.42 | +2.00% | 7,605 |
| 19/06/24 | 94.53 | -1.06% | 2,502 |
| 18/06/24 | 95.54 | +0.22% | 3,441 |
| 17/06/24 | 95.33 | -0.01% | 3,999 |
| 14/06/24 | 95.34 | -0.49% | 17,140 |
Delayed Quote Sao Paulo, June 20, 2024 at 08:52 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.8
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.99% | 803B | |
| -5.72% | 351B | |
| +18.94% | 324B | |
| +11.07% | 303B | |
| +16.96% | 243B | |
| +2.25% | 228B | |
| +11.15% | 217B | |
| +7.59% | 164B | |
| -3.65% | 155B |
- Stock Market
- Equities
- NOVO B Stock
- N1VO34 Stock
